---
title: "2025 国谈第四日上午场开启：华润三九、以岭药业入场 中药品种开始谈判"
description: "记者从 2025 年国家医保目录现场谈判与商保创新药目录价格协商现场获悉，2025 国谈第四日进程于 8 时左右开始，华润三九、健民药业、北京以岭药业、卫材、科睿药业等药企代表依次进场等待谈判。中药企业代表密集进场，预计中药品种开始谈判。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263867464.md"
published_at: "2025-11-02T00:59:20.000Z"
---

# 2025 国谈第四日上午场开启：华润三九、以岭药业入场 中药品种开始谈判

> 记者从 2025 年国家医保目录现场谈判与商保创新药目录价格协商现场获悉，2025 国谈第四日进程于 8 时左右开始，华润三九、健民药业、北京以岭药业、卫材、科睿药业等药企代表依次进场等待谈判。中药企业代表密集进场，预计中药品种开始谈判。

记者从 2025 年国家医保目录现场谈判与商保创新药目录价格协商现场获悉，2025 国谈第四日进程于 8 时左右开始，华润三九、健民药业、北京以岭药业、卫材、科睿药业等药企代表依次进场等待谈判。中药企业代表密集进场，预计中药品种开始谈判。

### Related Stocks

- [002603.CN - 以岭药业](https://longbridge.com/zh-CN/quote/002603.CN.md)
- [000999.CN - 华润三九](https://longbridge.com/zh-CN/quote/000999.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material | Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material | [Link](https://longbridge.com/zh-CN/news/265661137.md) |
| Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | [Link](https://longbridge.com/zh-CN/news/267815314.md) |
| Forget Regencell Bioscience: This blue chip drug maker is the boring compounder you need | Don't follow general market sentiment when it comes to these two stocks. | [Link](https://longbridge.com/zh-CN/news/277366138.md) |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, | [Link](https://longbridge.com/zh-CN/news/275124956.md) |
| InterRent REIT Publishes MD&A for Year Ended Dec. 31, 2025 | InterRent REIT reported a portfolio occupancy of 96.9% for December 2025, with average monthly rent increasing by 2.8% y | [Link](https://longbridge.com/zh-CN/news/277549019.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。